SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2025-09-16 19:37Core Viewpoint - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., has confirmed the legitimacy and effectiveness of the incentive plan for 2025, with no objections raised during the public notice period [1][2][4]. Trading Information Summary - As of September 16, 2025, the stock price closed at 35.78 yuan, with a turnover rate of 1.05% and a trading volume of 45,600 shares, resulting in a transaction amount of 162 million yuan [1]. - On the same day, the main funds experienced a net outflow of 12.4025 million yuan, while speculative funds saw a net inflow of 9.7896 million yuan, and retail investors had a net inflow of 2.6128 million yuan [1][4]. Company Announcement Summary - The Supervisory Board has verified the list of incentive plan participants, confirming that all individuals meet the necessary qualifications and are legitimate candidates, including directors, senior management, middle management, and technical personnel, excluding independent directors, supervisors, foreign employees, and shareholders holding more than 5% [1][2]. - The Board's Compensation and Assessment Committee also conducted a review of the incentive plan participants, affirming their qualifications and the absence of any disqualifying conditions [2].